АВ0-INCOMPATIBILITY IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: 15-YEARS EXPERIENCE OF R.M. GORBACHEVA MEMORIAL RESEARCH INSTITUTE FOR CHILDREN ONCOLOGY, HEMATOLOGY AND TRANSPLANTATION

Introduction. AB0-incompatibility in different types of allogeneic hematopoietic stem cell transplantation (HSCT) may be an additional aggravating factor for the development of immunological complications and decrease treatment efficacy.Materials and methods. From May 1999 to December 2015 in R.M. G...

Full description

Saved in:
Bibliographic Details
Main Authors: M. A. Kucher, D. E. Pevtcov, O. A. Makarenko, A. L. Alyanskiy, N. E. Ivanova, М. A. Estrina, E. V. Babenko, B. B. Bakhovadinov, L. S. Zubarovskaya, B. V. Afanasiev
Format: Article
Language:Russian
Published: ABV-press 2017-01-01
Series:Онкогематология
Subjects:
Online Access:https://oncohematology.abvpress.ru/ongm/article/view/215
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849241295445295104
author M. A. Kucher
D. E. Pevtcov
O. A. Makarenko
A. L. Alyanskiy
N. E. Ivanova
М. A. Estrina
E. V. Babenko
B. B. Bakhovadinov
L. S. Zubarovskaya
B. V. Afanasiev
author_facet M. A. Kucher
D. E. Pevtcov
O. A. Makarenko
A. L. Alyanskiy
N. E. Ivanova
М. A. Estrina
E. V. Babenko
B. B. Bakhovadinov
L. S. Zubarovskaya
B. V. Afanasiev
author_sort M. A. Kucher
collection DOAJ
description Introduction. AB0-incompatibility in different types of allogeneic hematopoietic stem cell transplantation (HSCT) may be an additional aggravating factor for the development of immunological complications and decrease treatment efficacy.Materials and methods. From May 1999 to December 2015 in R.M. Gorbacheva Memorial Research Institute for Children Oncology, Hematology and Transplantation 1131 patients with malignancies and hereditary diseases were included to the study, which were performed 1428 allogeneic HSCT: allogeneic unrelated – 814 (57.0 %), allogeneic related – 344 (24.1 %), haploidentical – 267 (18.7 %), umbilical cord blood in 3 patients (0.2 %). Age was 0–76 years, median – 25 years.Results. In 54.6 % of cases (n = 780) АВ0-incompatibility was determined: major – 37.8 % (n = 295); minor – 45.4 % (n = 354); combined – 16.8 % (n = 131). АВ0-incompatibility in allogeneic HSCT did not influence overall survival (p = 0.56), frequency of acute graftversus-host disease (GVHD) (p = 0.2). There was an increased frequency of acute GVHD in combination with reduced intensity conditioning regimens and АВ0-incompatibility (30.8 %) compared with myeloablative regimens (15.3 %; p = 0.002).Conclusion. The presence of АВ0-incompatibility is not a limiting factor to perform allogeneic HSCT, however, it demands high quality prophylaxis and sophisticated transfusion therapy to prevent immune complications.
format Article
id doaj-art-ebddda97dee7404792a4c2a2a2c73205
institution Kabale University
issn 1818-8346
2413-4023
language Russian
publishDate 2017-01-01
publisher ABV-press
record_format Article
series Онкогематология
spelling doaj-art-ebddda97dee7404792a4c2a2a2c732052025-08-20T04:00:13ZrusABV-pressОнкогематология1818-83462413-40232017-01-01114495510.17650/1818-8346-2016-11-4-49-55216АВ0-INCOMPATIBILITY IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: 15-YEARS EXPERIENCE OF R.M. GORBACHEVA MEMORIAL RESEARCH INSTITUTE FOR CHILDREN ONCOLOGY, HEMATOLOGY AND TRANSPLANTATIONM. A. Kucher0D. E. Pevtcov1O. A. Makarenko2A. L. Alyanskiy3N. E. Ivanova4М. A. Estrina5E. V. Babenko6B. B. Bakhovadinov7L. S. Zubarovskaya8B. V. Afanasiev9R.M. Gorbacheva Memorial Research Institute for Children Oncology, Hematology and Transplantation; Acad. I.P. Pavlov First Saint Petersburg State Medical UniversityR.M. Gorbacheva Memorial Research Institute for Children Oncology, Hematology and Transplantation; Acad. I.P. Pavlov First Saint Petersburg State Medical UniversityR.M. Gorbacheva Memorial Research Institute for Children Oncology, Hematology and Transplantation; Acad. I.P. Pavlov First Saint Petersburg State Medical UniversityR.M. Gorbacheva Memorial Research Institute for Children Oncology, Hematology and Transplantation; Acad. I.P. Pavlov First Saint Petersburg State Medical UniversityR.M. Gorbacheva Memorial Research Institute for Children Oncology, Hematology and Transplantation; Acad. I.P. Pavlov First Saint Petersburg State Medical UniversityR.M. Gorbacheva Memorial Research Institute for Children Oncology, Hematology and Transplantation; Acad. I.P. Pavlov First Saint Petersburg State Medical UniversityR.M. Gorbacheva Memorial Research Institute for Children Oncology, Hematology and Transplantation; Acad. I.P. Pavlov First Saint Petersburg State Medical UniversityR.M. Gorbacheva Memorial Research Institute for Children Oncology, Hematology and Transplantation; Acad. I.P. Pavlov First Saint Petersburg State Medical UniversityR.M. Gorbacheva Memorial Research Institute for Children Oncology, Hematology and Transplantation; Acad. I.P. Pavlov First Saint Petersburg State Medical UniversityR.M. Gorbacheva Memorial Research Institute for Children Oncology, Hematology and Transplantation; Acad. I.P. Pavlov First Saint Petersburg State Medical UniversityIntroduction. AB0-incompatibility in different types of allogeneic hematopoietic stem cell transplantation (HSCT) may be an additional aggravating factor for the development of immunological complications and decrease treatment efficacy.Materials and methods. From May 1999 to December 2015 in R.M. Gorbacheva Memorial Research Institute for Children Oncology, Hematology and Transplantation 1131 patients with malignancies and hereditary diseases were included to the study, which were performed 1428 allogeneic HSCT: allogeneic unrelated – 814 (57.0 %), allogeneic related – 344 (24.1 %), haploidentical – 267 (18.7 %), umbilical cord blood in 3 patients (0.2 %). Age was 0–76 years, median – 25 years.Results. In 54.6 % of cases (n = 780) АВ0-incompatibility was determined: major – 37.8 % (n = 295); minor – 45.4 % (n = 354); combined – 16.8 % (n = 131). АВ0-incompatibility in allogeneic HSCT did not influence overall survival (p = 0.56), frequency of acute graftversus-host disease (GVHD) (p = 0.2). There was an increased frequency of acute GVHD in combination with reduced intensity conditioning regimens and АВ0-incompatibility (30.8 %) compared with myeloablative regimens (15.3 %; p = 0.002).Conclusion. The presence of АВ0-incompatibility is not a limiting factor to perform allogeneic HSCT, however, it demands high quality prophylaxis and sophisticated transfusion therapy to prevent immune complications.https://oncohematology.abvpress.ru/ongm/article/view/215hematopoietic stem cell transplantationab0-incompatibility
spellingShingle M. A. Kucher
D. E. Pevtcov
O. A. Makarenko
A. L. Alyanskiy
N. E. Ivanova
М. A. Estrina
E. V. Babenko
B. B. Bakhovadinov
L. S. Zubarovskaya
B. V. Afanasiev
АВ0-INCOMPATIBILITY IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: 15-YEARS EXPERIENCE OF R.M. GORBACHEVA MEMORIAL RESEARCH INSTITUTE FOR CHILDREN ONCOLOGY, HEMATOLOGY AND TRANSPLANTATION
Онкогематология
hematopoietic stem cell transplantation
ab0-incompatibility
title АВ0-INCOMPATIBILITY IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: 15-YEARS EXPERIENCE OF R.M. GORBACHEVA MEMORIAL RESEARCH INSTITUTE FOR CHILDREN ONCOLOGY, HEMATOLOGY AND TRANSPLANTATION
title_full АВ0-INCOMPATIBILITY IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: 15-YEARS EXPERIENCE OF R.M. GORBACHEVA MEMORIAL RESEARCH INSTITUTE FOR CHILDREN ONCOLOGY, HEMATOLOGY AND TRANSPLANTATION
title_fullStr АВ0-INCOMPATIBILITY IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: 15-YEARS EXPERIENCE OF R.M. GORBACHEVA MEMORIAL RESEARCH INSTITUTE FOR CHILDREN ONCOLOGY, HEMATOLOGY AND TRANSPLANTATION
title_full_unstemmed АВ0-INCOMPATIBILITY IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: 15-YEARS EXPERIENCE OF R.M. GORBACHEVA MEMORIAL RESEARCH INSTITUTE FOR CHILDREN ONCOLOGY, HEMATOLOGY AND TRANSPLANTATION
title_short АВ0-INCOMPATIBILITY IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: 15-YEARS EXPERIENCE OF R.M. GORBACHEVA MEMORIAL RESEARCH INSTITUTE FOR CHILDREN ONCOLOGY, HEMATOLOGY AND TRANSPLANTATION
title_sort ав0 incompatibility in allogeneic hematopoietic stem cell transplantation 15 years experience of r m gorbacheva memorial research institute for children oncology hematology and transplantation
topic hematopoietic stem cell transplantation
ab0-incompatibility
url https://oncohematology.abvpress.ru/ongm/article/view/215
work_keys_str_mv AT makucher av0incompatibilityinallogeneichematopoieticstemcelltransplantation15yearsexperienceofrmgorbachevamemorialresearchinstituteforchildrenoncologyhematologyandtransplantation
AT depevtcov av0incompatibilityinallogeneichematopoieticstemcelltransplantation15yearsexperienceofrmgorbachevamemorialresearchinstituteforchildrenoncologyhematologyandtransplantation
AT oamakarenko av0incompatibilityinallogeneichematopoieticstemcelltransplantation15yearsexperienceofrmgorbachevamemorialresearchinstituteforchildrenoncologyhematologyandtransplantation
AT alalyanskiy av0incompatibilityinallogeneichematopoieticstemcelltransplantation15yearsexperienceofrmgorbachevamemorialresearchinstituteforchildrenoncologyhematologyandtransplantation
AT neivanova av0incompatibilityinallogeneichematopoieticstemcelltransplantation15yearsexperienceofrmgorbachevamemorialresearchinstituteforchildrenoncologyhematologyandtransplantation
AT maestrina av0incompatibilityinallogeneichematopoieticstemcelltransplantation15yearsexperienceofrmgorbachevamemorialresearchinstituteforchildrenoncologyhematologyandtransplantation
AT evbabenko av0incompatibilityinallogeneichematopoieticstemcelltransplantation15yearsexperienceofrmgorbachevamemorialresearchinstituteforchildrenoncologyhematologyandtransplantation
AT bbbakhovadinov av0incompatibilityinallogeneichematopoieticstemcelltransplantation15yearsexperienceofrmgorbachevamemorialresearchinstituteforchildrenoncologyhematologyandtransplantation
AT lszubarovskaya av0incompatibilityinallogeneichematopoieticstemcelltransplantation15yearsexperienceofrmgorbachevamemorialresearchinstituteforchildrenoncologyhematologyandtransplantation
AT bvafanasiev av0incompatibilityinallogeneichematopoieticstemcelltransplantation15yearsexperienceofrmgorbachevamemorialresearchinstituteforchildrenoncologyhematologyandtransplantation